Lubin S - Search Results

1

Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.

Chiorean EG, Chiaro MD, Tempero MA, Malafa MP, Benson AB, Cardin DB, Christensen JA, Chung V, Czito B, Dillhoff M, Donahue TR, Dotan E, Fountzilas C, Glazer ES, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Masood A, Moravek C, Nakakura EK, Narang AK, Nardo L, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Truty MJ, Vollmer C, Wolff RA, Wolpin BM, Rn BM, Lubin S, Darlow SD. Chiorean EG, et al. Among authors: lubin s. J Natl Compr Canc Netw. 2023 Jul;21(7):753-782. doi: 10.6004/jnccn.2023.0034. J Natl Compr Canc Netw. 2023. PMID: 37433437

2

Lamin A/C cardiomyopathy presenting as high-grade atrioventricular (AV) block, atrial fibrillation, heart failure and ventricular tachycardia in a single-family cluster.

Lubin SR, Paulraj S, Ahmed J. Lubin SR, et al. BMJ Case Rep. 2023 Jun 22;16(6):e255605. doi: 10.1136/bcr-2023-255605. BMJ Case Rep. 2023. PMID: 37348923

3

Patients Who Decompensate and Trigger Rapid Response Immediately Upon Hospital Admission Have Higher Mortality Than Equivalent Patients Without Rapid Responses.

Lykins V JD, Freedman MT, Zemore Z, Sedhai YR, Lubin S, Sessler CN, Hogan C, Kashiouris MG. Lykins V JD, et al. Among authors: lubin s. J Patient Saf. 2023 Aug 1;19(5):300-304. doi: 10.1097/PTS.0000000000001139. Epub 2023 Jun 14. J Patient Saf. 2023. PMID: 37310865

4

Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor.

Perera V, Wang Z, Lubin S, Christopher LJ, Chen W, Xu S, Seiffert D, DeSouza M, Murthy B. Perera V, et al. Among authors: lubin s. Sci Rep. 2022 Dec 23;12(1):22239. doi: 10.1038/s41598-022-25936-2. Sci Rep. 2022. PMID: 36564395 Free PMC article. Clinical Trial.

5

Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment.

Perera V, Abelian G, Li D, Wang Z, Zhang L, Lubin S, Bello A, Murthy B. Perera V, et al. Among authors: lubin s. Clin Pharmacokinet. 2022 Oct;61(10):1405-1416. doi: 10.1007/s40262-022-01150-1. Epub 2022 Jul 30. Clin Pharmacokinet. 2022. PMID: 35906349 Free PMC article. Clinical Trial.

6

Viscoelastic Hemostatic Assays for Orthopedic Trauma and Elective Procedures.

Mamczak CN, Speybroeck J, Stillson JE, Dynako J, Piscoya A, Peck EE, Aboukhaled M, Cancel E, McDonald M, Garcia D, Lovejoy J, Lubin S, Stanton R, Kutcher ME. Mamczak CN, et al. Among authors: lubin s. J Clin Med. 2022 Jul 12;11(14):4029. doi: 10.3390/jcm11144029. J Clin Med. 2022. PMID: 35887803 Free PMC article. Review.

7

Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor.

Perera V, Wang Z, Lubin S, Christopher LJ, Chen W, Xu S, Seiffert D, DeSouza M, Murthy B. Perera V, et al. Among authors: lubin s. Cardiol Ther. 2022 Sep;11(3):407-419. doi: 10.1007/s40119-022-00266-6. Epub 2022 May 31. Cardiol Ther. 2022. PMID: 35641780 Free PMC article.

8

Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants.

Perera V, Wang Z, Lubin S, Ueno T, Shiozaki T, Chen W, Xu X, Seiffert D, DeSouza M, Murthy B. Perera V, et al. Among authors: lubin s. Sci Rep. 2022 Mar 25;12(1):5165. doi: 10.1038/s41598-022-08768-y. Sci Rep. 2022. PMID: 35338177 Free PMC article. Clinical Trial.

9

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.

Moore K, Thakkar N, Magee M, Sevinsky H, Vakkalagadda B, Lubin S, Llamoso C, Ackerman P. Moore K, et al. Among authors: lubin s. Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0225121. doi: 10.1128/aac.02251-21. Epub 2022 Mar 22. Antimicrob Agents Chemother. 2022. PMID: 35315687 Free PMC article.

10

Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants.

Perera V, Abelian G, Li D, Wang Z, Zhang L, Lubin S, Chen W, Bello A, Murthy B. Perera V, et al. Among authors: lubin s. Clin Pharmacokinet. 2022 Jun;61(6):857-867. doi: 10.1007/s40262-022-01110-9. Epub 2022 Mar 9. Clin Pharmacokinet. 2022. PMID: 35262846 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

61 results

Search Page